(Reuters) - Eli Lilly has lost a patent case in Germany over its blockbuster Alimta lung cancer drug to generic producer Actavis, hitting the U.S. drugmaker's future sales hopes for the medicine.
Alimta generated worldwide sales of $2.79 billion for Lilly last year, making the medicine its biggest-selling product.
00:59 Federal judge tosses out life sentences for DC sniper Malvo27
18:43 Another appeals court rules against President Trump's travel banÂ13
18:19 Federal appeals court largely maintains freeze of Trump’s travel ban21
18:07 Trump's Travel Ban Remains Frozen After Appeals Court Ruling19